The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action
- PMID: 37008163
- PMCID: PMC10065839
- DOI: 10.1097/HS9.0000000000000872
The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action
Erratum in
-
Correction Notice-The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action.Hemasphere. 2023 Apr 27;7(5):e897. doi: 10.1097/HS9.0000000000000897. eCollection 2023 May. Hemasphere. 2023. PMID: 37125258 Free PMC article.
Abstract
Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the research and diagnostic advances in the field, real world evidence, arising from international neutropenia patient registries and scientific networks, has shown that the diagnosis and management of neutropenic patients is mostly based on the physicians' experience and local practices. Therefore, experts participating in the European Network for the Innovative Diagnosis and Treatment of Chronic Neutropenias have collaborated under the auspices of the European Hematology Association to produce recommendations for the diagnosis and management of patients across the whole spectrum of chronic neutropenias. In the present article, we describe evidence- and consensus-based guidelines for the definition and classification, diagnosis, and follow-up of patients with chronic neutropenias including special entities such as pregnancy and the neonatal period. We particularly emphasize the importance of combining the clinical findings with classical and novel laboratory testing, and advanced germline and/or somatic mutational analyses, for the characterization, risk stratification, and monitoring of the entire spectrum of neutropenia patients. We believe that the wide clinical use of these practical recommendations will be particularly beneficial for patients, families, and treating physicians.
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Conflict of interest statement
FF: Advisory Board honorarium from X4 Pharmaceuticals. PEN: Consultant for X4 Pharmaceuticals. JP: Consultant to Chiesi Canada Ltd. DCD: Consultant and research support: Amgen, X4Pharma, Emendo Bio; data safety monitoring committee: Galderma, Omeros, X4Pharma, Hoffman-LaRoche, Insmed; consultant: Boerhinger-Ingelheim, Prolong,Coherus, Spectrum, Shire, Seattle Genetics. CD: Advisory Board honorarium from Gilead, Novartis, Pfizer, Rockets, Sobi. HAP: Advisory Board honorarium from X4 Pharmaceuticals. All the other authors have no conflicts of interest to disclose.
Figures
References
-
- Donadieu J, Beaupain B, Fenneteau O, et al. . Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. Br J Haematol. 2017;179:557–574. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources